Working… Menu

A Study of PRN1008 in Patients With Pemphigus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03762265
Recruitment Status : Active, not recruiting
First Posted : December 3, 2018
Last Update Posted : April 26, 2021
Information provided by (Responsible Party):
Sanofi ( Principia Biopharma, a Sanofi Company )

Brief Summary:
This is a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (Blinded Treatment Period) followed by an Open-Label Extension Period intended to evaluate the efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the Open-Label Extension Period, eligible patients may continue in a Long Term Extension Period of 48 weeks.

Condition or disease Intervention/treatment Phase
Pemphigus Drug: PRN1008 Oral Tablet Drug: Placebo Oral Tablet Phase 3

Detailed Description:

Approximately 120 male or female patients with newly diagnosed or relapsing moderate to severe pemphigus (pemphigus vulgaris [PV] or pemphigus foliaceus [PF]) will be enrolled in the trial worldwide.

The trial will last 68 weeks (approximately 17 months) for each participant. For patients eligible to enroll in the Long Term Extension, the trial may last up to 116 weeks.

Patients will be randomized at Day 1, using a 1:1 ratio to receive PRN1008 or placebo twice per day, by relapsing/newly diagnosed disease history (newly diagnosed defined as within 6 months of Screening).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 131 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus
Actual Study Start Date : January 8, 2019
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : February 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pemphigus

Arm Intervention/treatment
Experimental: Experimental Drug: PRN1008 Oral Tablet
Bruton's agammaglobulinemia tyrosine kinase (BTK) inhibitor

Placebo Comparator: Placebo Drug: Placebo Oral Tablet

Primary Outcome Measures :
  1. The proportion of patients who are in Complete Remission (CR) from Week ≤ 29 to Week 37 with prednisone dose of ≤5 mg/day [ Time Frame: 37 Weeks ]
    Complete Remission (CR) defined as the absence of new and established lesions

Secondary Outcome Measures :
  1. Cumulative Corticosteroids (CS) dose over first 36 weeks (to Week 37) [ Time Frame: 37 Weeks ]
    Cumulative CS dose over first 36 weeks (to Week 37)

  2. Change in EuroQOL-5 Dimension 5 Level (EQ-5D-5L) score from baseline to Weeks 5, 13, 25, and 61 [ Time Frame: 61 Weeks ]
    EQ-5D-5L questionnaire has 5 dimensions: "Mobility", "Self-Care," "Usual Activities", "Pain/Discomfort", "Anxiety/Depression", and all dimensions are described by 5 problem levels.

  3. Change in Autoimmune Bullous Disease Quality of Life (ABQOL) from baseline to Weeks 5, 13, 25, and 61 [ Time Frame: 61 Weeks ]
    The ABQOL questionnaire is a 17 item questionnaire assessing quality of life in patients with autoimmune blistering diseases

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female aged 18-80 years old with moderate to severe pemphigus, newly diagnosed or relapsing pemphigus vulgaris (PD) or pemphigus foliaceus (PF); positive anti-dsg1 or 3 autoantibody titer
  • Laboratory clearance with adequate hematologic, hepatic, and renal function
  • Female patients who are of reproductive potential must agree for the duration of active treatment to use an effective means of contraception
  • Able to provide written informed consent

Exclusion Criteria:

  • Previous use of a Bruton's tyrosine kinase (BTK) inhibitor
  • Pregnant or lactating women
  • Clinically significant abnormalities, ECG findings or poorly controlled atrial fibrillation
  • A history of malignancy of any type other than surgically excised non-melanoma skin cancers or in situ cervical cancer within 5 years before Day 1
  • Use of excluded medications within specified timeframes (proton pump inhibitors, immunologic response modifiers, investigational drugs, CYP3A inducers or inhibitors, CYP3A-sensitive substrates)
  • History of drug abuse or excessive alcohol use
  • Blood or blood product donation of a unit or more within 4 weeks
  • Live vaccine within 28 days prior to Day 1 or plan to receive one during the trial
  • Clinically significant diseases, positive at Screening HIV and hepatitis A and B, history of serious infections and active latent tuberculosis (TB)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03762265

Show Show 88 study locations
Sponsors and Collaborators
Principia Biopharma, a Sanofi Company
Layout table for additonal information
Responsible Party: Principia Biopharma, a Sanofi Company Identifier: NCT03762265    
Other Study ID Numbers: EFC17092
PRN1008-012 ( Other Identifier: Principia Biopharma )
First Posted: December 3, 2018    Key Record Dates
Last Update Posted: April 26, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sanofi ( Principia Biopharma, a Sanofi Company ):
Pemphigus Vulgaris (PV)
Pemphigus Foliaceus (PF)
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Vesiculobullous
Skin Diseases
Autoimmune Diseases
Immune System Diseases